The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Final results from the first-in-human phase 1 study of arlo-cel represent the longest follow-up with GPRC5D CAR T-cell therapy in relapsed or refractory
The study, led by Raúl Azibeiro Melchor, of Hospital Universitario de Salamanca in Spain, will be presented at the Fourteenth Annual Meeting of
Patients with telomere biology disorders (TBDs) exhibited substantial hematologic and multiorgan morbidity as well as frequent clonal hematopoiesis with a high rate of
The analysis, led by Elias Jabbour, MD, of University of Texas MD Anderson Cancer Center in Houston, was presented at the Fourteenth Annual
Elritercept, an investigational modified activin receptor type IIA ligand trap, was well-tolerated and associated with rapid, durable transfusion and erythroid responses, including in
Ofirnoflast, a first-in-class allosteric NEK7 inhibitor, showed favorable safety and clinically significant efficacy in patients with low-risk myelodysplastic syndromes (LR-MDS) refractory to erythropoietin
The study, led by Pina Gabriela Gálvez Zavala Registro, of Universidad Peruana Cayetano Heredia in Lima, Peru, compared patients in the Spanish Group
The investigators, led by Ryan C Lynch, MD, of Fred Hutchinson Cancer Center in Seattle, Washington, published their findings in the Journal of
The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal
The nanobody-based CD5 CAR T-cells had superior antigen-dependent activation compared with humanized CD5 CAR T-cells, said lead author, Jing Pan, MD, PhD, of
